News & Views
National Platforms Boost Singapore's Drug Development Efforts
Jul 22 2019 Read 341 Times
The nation's drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development.
These national platforms aim to bridge the 'valley of death' between basic science research and pharmaceutical enterprises. They will also serve to catalyse collaboration across industry, research institutes, academia, and the hospitals; as well as nurture a strong pool of scientific talent for Singapore's biomedical ecosystem.
These announcements were made during the opening ceremony of the Experimental Drug Development Centre (EDDC) in Biopolis, officiated by Mr Heng Swee Keat, Deputy Prime Minister and Minister for Finance, and Chairman of the National Research Foundation (NRF).
EDDC is a national platform for drug discovery and development to channel high potential drug candidates toward realising commercial outcomes for Singapore, as well as clinical outcomes that will benefit Singaporeans. EDDC integrates A*STAR's Experimental Therapeutics Centre (ETC), the clinical development unit known as Drug Discovery and Development (D3), and the Experimental Biotherapeutics Centre (EBC).
Also launched, the Target Translation Consortium (TTC) brings together A*STAR, Duke-NUS Medical School, Lee Kong Chian School of Medicine, Nanyang Technological University, National Healthcare Group, National University of Singapore, National University Health System, and SingHealth. Helmed by EDDC, this new TTC coordinates early-stage drug discovery efforts across academia, healthcare institutions, and government agencies. This collaborative approach is an important competitive edge for Singapore's biomedical ecosystem amidst an increasingly sophisticated drug discovery and development space.
To complement these two new platforms, the Singapore Therapeutics Development Review (STDR) grant scheme was also announced. STDR consolidates three separate schemes by A*STAR, the National Health Innovation Centre Singapore (NHIC), as well as the Singapore-MIT Alliance for Research and Technology (SMART); into a new grant that funds early-stage projects up to S$750,000. It combines the expertise and resources of all three organisations, streamlining the assessment and feedback process for promising drug discovery and development projects.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
Articles Finding an easy, cost-effective way to break into new markets Exploring safe and intelligent multi-application liquid nitrogen cooling via auto-fill technology Characterisation o...
View all digital editions
Sep 19 2019 Hyderabad, India
Sep 23 2019 Ulm Germany
Sep 24 2019 Sao Paulo, Brazil
Sep 24 2019 Karachi, Pakistan
Sep 24 2019 Basel, Switzerland